{"name":"Innovent Biologics (Suzhou) Co. Ltd.","slug":"innovent-biologics-suzhou-co-ltd","ticker":"","exchange":"","domain":"innoventbiologicssuzhou.com","description":"","hq":"Suzhou","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"oncology","drugs":[{"name":"IBI308","genericName":"IBI308","slug":"ibi308","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI362","genericName":"IBI362","slug":"ibi362","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI303","genericName":"IBI303","slug":"ibi303","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI305","genericName":"IBI305","slug":"ibi305","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI343","genericName":"IBI343","slug":"ibi343","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI354","genericName":"IBI354","slug":"ibi354","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI301 plus CHOP","genericName":"IBI301 plus CHOP","slug":"ibi301-plus-chop","indication":"Lymphoma (in combination with CHOP chemotherapy)","status":"phase_3"},{"name":"IBI306","genericName":"IBI306","slug":"ibi306","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"IBI310","genericName":"IBI310","slug":"ibi310","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"IBI310&Sintilimab","genericName":"IBI310&Sintilimab","slug":"ibi310-sintilimab","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"IBI343,Gemcitabine, Albumin-bound Paclitaxel","genericName":"IBI343,Gemcitabine, Albumin-bound Paclitaxel","slug":"ibi343-gemcitabine-albumin-bound-paclitaxel","indication":"Breast cancer","status":"phase_2"},{"name":"IBI343,sintilimab,oxaliplatin,S-1","genericName":"IBI343,sintilimab,oxaliplatin,S-1","slug":"ibi343-sintilimab-oxaliplatin-s-1","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"IBI363","genericName":"IBI363","slug":"ibi363","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"dose 1 IBI302","genericName":"dose 1 IBI302","slug":"dose-1-ibi302","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"paclitaxel/Gemcitabine/Liposomal doxorubicin","genericName":"paclitaxel/Gemcitabine/Liposomal doxorubicin","slug":"paclitaxel-gemcitabine-liposomal-doxorubicin","indication":"Metastatic breast cancer, Metastatic pancreatic cancer, Metastatic ovarian cancer","status":"phase_3"},{"name":"placebo /IBI112","genericName":"placebo /IBI112","slug":"placebo-ibi112","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"IBI318","genericName":"IBI318","slug":"ibi318","indication":"Other","status":"phase_2"},{"name":"Placebo2","genericName":"Placebo2","slug":"placebo2","indication":"Other","status":"phase_3"},{"name":"dose-4 group","genericName":"dose-4 group","slug":"dose-4-group","indication":"Other","status":"phase_1"},{"name":"IBI128","genericName":"IBI128","slug":"ibi128","indication":"Other","status":"phase_2"},{"name":"IBI308 200mg","genericName":"IBI308 200mg","slug":"ibi308-200mg","indication":"Other","status":"phase_1"},{"name":"IBI356","genericName":"IBI356","slug":"ibi356","indication":"Other","status":"phase_2"},{"name":"Intensive treatment","genericName":"Intensive treatment","slug":"intensive-treatment","indication":"Other","status":"marketed"},{"name":"Placebo SC Q4W","genericName":"Placebo SC Q4W","slug":"placebo-sc-q4w","indication":"Other","status":"phase_3"},{"name":"Placebo1","genericName":"Placebo1","slug":"placebo1","indication":"Other","status":"phase_3"},{"name":"regular treatment","genericName":"regular treatment","slug":"regular-treatment","indication":"Other","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Teprotumumab N01","genericName":"Teprotumumab N01","slug":"teprotumumab-n01","indication":"Thyroid eye disease (TED) / Graves' ophthalmopathy","status":"marketed"}]}],"pipeline":[{"name":"IBI308","genericName":"IBI308","slug":"ibi308","phase":"phase_3","mechanism":"IBI308 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"IBI362","genericName":"IBI362","slug":"ibi362","phase":"phase_3","mechanism":"IBI362 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","indications":["Non-small cell lung cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"IBI303","genericName":"IBI303","slug":"ibi303","phase":"phase_3","mechanism":"IBI303 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"IBI305","genericName":"IBI305","slug":"ibi305","phase":"phase_3","mechanism":"IBI305 is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"IBI318","genericName":"IBI318","slug":"ibi318","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI343","genericName":"IBI343","slug":"ibi343","phase":"phase_3","mechanism":"IBI343 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","indications":["Non-small cell lung cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"IBI354","genericName":"IBI354","slug":"ibi354","phase":"phase_3","mechanism":"IBI354 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","indications":["Non-small cell lung cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"Placebo2","genericName":"Placebo2","slug":"placebo2","phase":"phase_3","mechanism":"Placebo2 does not have an active pharmacological mechanism; it is designed as a control in clinical trials.","indications":[],"catalyst":""},{"name":"dose-4 group","genericName":"dose-4 group","slug":"dose-4-group","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI128","genericName":"IBI128","slug":"ibi128","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI301 plus CHOP","genericName":"IBI301 plus CHOP","slug":"ibi301-plus-chop","phase":"phase_3","mechanism":"IBI301 is a PD-L1 inhibitor combined with CHOP chemotherapy to enhance anti-tumor immune response while providing cytotoxic chemotherapy.","indications":["Lymphoma (in combination with CHOP chemotherapy)"],"catalyst":""},{"name":"IBI306","genericName":"IBI306","slug":"ibi306","phase":"phase_3","mechanism":"IBI306 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"IBI308 200mg","genericName":"IBI308 200mg","slug":"ibi308-200mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI310","genericName":"IBI310","slug":"ibi310","phase":"phase_3","mechanism":"IBI310 is a bispecific antibody that simultaneously engages PD-1 on T cells and TIM-3 on tumor-infiltrating lymphocytes to enhance anti-tumor immune responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"IBI310&Sintilimab","genericName":"IBI310&Sintilimab","slug":"ibi310-sintilimab","phase":"phase_3","mechanism":"IBI310 is a bispecific antibody that simultaneously blocks CTLA-4 and TIM-3 checkpoints to enhance anti-tumor immunity, while Sintilimab is a PD-1 inhibitor that releases PD-1-mediated immune suppression.","indications":["Advanced or metastatic solid tumors (Phase 3 development)","Non-small cell lung cancer"],"catalyst":""},{"name":"IBI343,Gemcitabine, Albumin-bound Paclitaxel","genericName":"IBI343,Gemcitabine, Albumin-bound Paclitaxel","slug":"ibi343-gemcitabine-albumin-bound-paclitaxel","phase":"phase_2","mechanism":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis by interfering with DNA polymerase.","indications":["Breast cancer","Ovarian cancer","Pancreatic cancer","Non-small cell lung cancer"],"catalyst":""},{"name":"IBI343,sintilimab,oxaliplatin,S-1","genericName":"IBI343,sintilimab,oxaliplatin,S-1","slug":"ibi343-sintilimab-oxaliplatin-s-1","phase":"phase_2","mechanism":"Programmed death-ligand 1 inhibitor","indications":["Non-small cell lung cancer","Colorectal cancer"],"catalyst":""},{"name":"IBI356","genericName":"IBI356","slug":"ibi356","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IBI363","genericName":"IBI363","slug":"ibi363","phase":"phase_3","mechanism":"IBI363 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TIM-3 on T cells to enhance anti-tumor immune responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"Intensive treatment","genericName":"Intensive treatment","slug":"intensive-treatment","phase":"marketed","mechanism":"Inhibits programmed death-ligand 1 (PD-L1) to restore T-cell mediated immune response against cancer cells.","indications":[],"catalyst":""},{"name":"Placebo SC Q4W","genericName":"Placebo SC Q4W","slug":"placebo-sc-q4w","phase":"phase_3","mechanism":"This is a placebo control used in clinical trials and does not exert any active pharmacological effect.","indications":[],"catalyst":""},{"name":"Placebo1","genericName":"Placebo1","slug":"placebo1","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Teprotumumab N01","genericName":"Teprotumumab N01","slug":"teprotumumab-n01","phase":"marketed","mechanism":"Teprotumumab is a human monoclonal antibody that inhibits insulin-like growth factor-1 receptor (IGF-1R) signaling to reduce inflammation and fibrosis in thyroid eye disease.","indications":["Thyroid eye disease (TED) / Graves' ophthalmopathy"],"catalyst":""},{"name":"dose 1 IBI302","genericName":"dose 1 IBI302","slug":"dose-1-ibi302","phase":"phase_3","mechanism":"IBI302 is an anti-PD-1 monoclonal antibody that works by binding to the PD-1 receptor and blocking its interaction with PD-L1, thereby enhancing T-cell mediated immune response.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"paclitaxel/Gemcitabine/Liposomal doxorubicin","genericName":"paclitaxel/Gemcitabine/Liposomal doxorubicin","slug":"paclitaxel-gemcitabine-liposomal-doxorubicin","phase":"phase_3","mechanism":"Paclitaxel inhibits microtubule dynamics, Gemcitabine is a nucleoside analog that inhibits DNA synthesis, and Liposomal doxorubicin is an anthracycline antibiotic that intercalates DNA.","indications":["Metastatic breast cancer, Metastatic pancreatic cancer, Metastatic ovarian cancer"],"catalyst":""},{"name":"placebo /IBI112","genericName":"placebo /IBI112","slug":"placebo-ibi112","phase":"phase_3","mechanism":"IBI112 is an anti-PD-1 monoclonal antibody.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"regular treatment","genericName":"regular treatment","slug":"regular-treatment","phase":"marketed","mechanism":"Unable to determine specific mechanism without additional drug identifier or name.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNODdrbjVQREpWN1Q4Vk5qNDQ4ekROMjdCck5BWWlwY0Q1Y0Z5cWlEUE5xZWpiS2g5X3RuSDJMTUREdFF4dmVDWEp2THdtOWJHSkxxYjNOTm40bjY4MEFoQ1JLZ2xWbk5iOHppNTZ1LUdfems1OEdGeEd2V0pweVFoUDlpcERDbFYtQ2VfSnF0RVd2WlFSZkgyWFJHWmZzcG8?oc=5","date":"2026-02-18","type":"deal","source":"BioWorld News","summary":"Gilead-Genhouse's $1.5B+ deal boosts synthetic lethality push - BioWorld News","headline":"Gilead-Genhouse's $1.5B+ deal boosts synthetic lethality push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNRG12S3NpMEktUmxVUjBCdlhJRFljTjNZbUhFVkZWd05OcVVvTFFNTVdUSDNzTW1BMHQ3U3VjejB1bGlSYTAzQ3k4OFZSa1Q3dHBMbDB1LXRQZHh3Tjl1YVB6LV9hakhBM1BudWRKT3NIOUYtY0t2TUJoWFl4ZHgzUkdwb0g4U2xncEtJOEQ5OExrZVNWT051YTF0QTQwU3lFSFczNS1kZDhwZjZZdnUyRHR1YTU0UVBWZHRDbVJxcDRGU3N4SUxNNGs5Yk90V3JGbEhrRzc3dENOeVlDNC1NVEJWS3hOckZZUkYtaXRPX1RwdWRiTmZib21QcVpJYWM?oc=5","date":"2026-01-13","type":"deal","source":"Citeline News & Insights","summary":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","headline":"Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNOWJaSWpCUjgwMkc5MXQxd2VLaW5DQTlOSnV1c0dhQ2VmdlBEdy1VWVJyVzZjcWVXenlDNC0wQnQ1RGJXbndzcEJUUDRNaXVDRkU0akF5b0FoSUxoLTA1T2syR2ZkY2pjRk9mSDhiSkFDVUd1WktNaTV4cklodk52R0lNZ1p5VlJjZmYyUA?oc=5","date":"2025-11-28","type":"pipeline","source":"pharmaphorum","summary":"Innovent gets OK for China's first home-grown IL-23p19 drug - pharmaphorum","headline":"Innovent gets OK for China's first home-grown IL-23p19 drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOT0lsd0Y3YU91RUlLM3FqRFFJb3JQZ0FyZWRvV2VrWjBuQWZNbXBCU190SFJFR2hHNVRVQlZ0R2VsZWw5MTlhQksxTVJ2U2U5LTY4MmdVV1FsamE4X2FEcU9TejdleThHbmhmMW1GdlZ3ek1SWkxuaU50WUhWU3dIZzlucXIyd21oM2dFbXBpaC0tZGlEY2l3aXp0ZEZFcVdyb0pjSUN0cjdnVFlNbE1TdjlIdks2VjVuQ1E?oc=5","date":"2025-10-22","type":"deal","source":"WSJ","summary":"China’s Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion - WSJ","headline":"China’s Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOekRsY19ta3BCYTZjSFE1S0NSenRYWmlBd21zWW5aT04zWGc3NTN0YklIZ1VtMHg2U2dORk13Q0NTeEl2Yk5sWlJRNDVQa2VOS3dSZTRPdUU0ZUd6clZmRG1XVllfMjJMbkhLYWo5S3RPd3pXZmhBODd5c0pFYXBnR3Y3SzM5cURXMDZNZFpoNlZ4U2ZZLUE?oc=5","date":"2025-10-22","type":"pipeline","source":"BioPharma Dive","summary":"Takeda stakes more than $11B on cancer drugs from China - BioPharma Dive","headline":"Takeda stakes more than $11B on cancer drugs from China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxONGttTWd4UzA1dGpVX3hXM2J1Y0ljb1BEeWl6cEVsbEQzUnktU05INTdzZXBSN1U1N0JScHl3X0NZbFM5UXRudDNJV0FnQTVCSm1hLURDZ2ZUUTRRWWpCUE5oaENjdnZDWlFjNGMxOFFKY3YwYmFZQTBpSnRHeDVUdHZmVjJFbVpSSmEybl8tZXlxV0hSWVZLUmMzMG04eGs1NGVzNE1NWDQ?oc=5","date":"2025-10-22","type":"deal","source":"BioWorld News","summary":"Innovent rings up $11.4B deal with Takeda for three I-O/ADC assets - BioWorld News","headline":"Innovent rings up $11.4B deal with Takeda for three I-O/ADC assets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPSVFUNHNGODFzT3AxVUlEUUxQN0owTVB2QlAxMkZOa05lV0dVOGpPOVItcDlRZ2lUNkFham9LUEMzUzN1QUh0MExmZ0dKOUJlUzNiSWUzUnBmY1k4OXUtVndCWm0yd0pNc1VwVWp3NFNGUmZlZVZxbmk2TVBCMmlSOEM1Ym0wNzAyeGRUWGdzeHlmVnFvdDcw?oc=5","date":"2025-06-30","type":"pipeline","source":"The Straits Times","summary":"China’s first weight loss drug emerges with its nascent market poised for rapid growth - The Straits Times","headline":"China’s first weight loss drug emerges with its nascent market poised for rapid growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOdVlKMlEyakxpZWJFSTBoaExBXzlsWV9FamxzQTFFMjZ0V3kyNmNEOUloSWxRM3JYOHFDQ29fWTk5Z1NQcjRqb0xtenctMWVWWTE4Mk5xa1NTTzlTRm5NMEhKMFBxOTNaU3NTa0FaR3ExbGZSTUVISm9tdjNialc4XzBkYXZDbG53ZU1QcnJlLWxmN3phcmtjZVUtRkZHREg0MTVOV01kcDZtOTJUNlZNbA?oc=5","date":"2025-06-27","type":"pipeline","source":"Bloomberg.com","summary":"Innovent Wins China Nod For Obesity Drug Rivaling Novo, Lilly - Bloomberg.com","headline":"Innovent Wins China Nod For Obesity Drug Rivaling Novo, Lilly","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQVHI4MG5idDZaMUVwODRYVXZIcEhlbFlOaFpvQkVVaDdwNFMzYmdURWlkY3JHM01LX2dSY01HdXU3MG9wYjFtSUcyU2VGVGd6amJYc2tnQVpEd3R0dlE2aHhLMEF1ZXFYN29OVlRldzYtd25VdmtWWjE4a1RJNFZKbXpwNGU4ZGxDc0lmdmY1LWFTSkRmNi1TU05wTQ?oc=5","date":"2025-06-03","type":"pipeline","source":"BioWorld News","summary":"Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B - BioWorld News","headline":"Astellas nabs Evopoint’s CLDN18.2-targeting ADC for $1.34B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQa0hwMk1RSk5aN3ZtLVlZOC1ESC1NaHI2SUlXZVRHc01tQWp1N2VfeDBlN2xwdUFjWGNSZTJjVWJhOWd6c0M2YWhDc29odURaVHpnbzVGUGFla01EV0hQaWx2Ny1DOEpPYzY4dzdIcl9qMzFYQkpiZnVaWFpXYXg1V1BVNzZzMEpWOHZPWUNseFFjZ3NEaElBZjZiOFAzUVJLb2FWdHZ2TWlTTkhwNGwzTW40UXpqSXNmaXYzb3Y4TUZ4UQ?oc=5","date":"2024-11-04","type":"pipeline","source":"Yicai Global","summary":"Chinese Drugmaker Innovent Rallies After Ditching Sale of Unit's Shares to Founder - Yicai Global","headline":"Chinese Drugmaker Innovent Rallies After Ditching Sale of Unit's Shares to Founder","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNNzBlREkzQ1h0ak0tX1pGbFllM0w3TGRkR2RjcTFXV2ExVjB5RWFuQ3hBYmdfcFZmR25fQ2MwaXNTcTN0bW5uUlAtTFN5QUJZelRlR05fYzVnd1hJRU9xTk5LaXhPMXJHa243SlQ5SzRudDh6RFpxdGF4OU9PQmZwb0Z2bnZMZHJTWGxSX1BGT0hCYTQ?oc=5","date":"2024-02-08","type":"regulatory","source":"Frontiers","summary":"Creating China’s Biosimilar Drugs Regulatory System: A Calculated Approach - Frontiers","headline":"Creating China’s Biosimilar Drugs Regulatory System: A Calculated Approach","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1Mb0REVGt6WWJCTlRfRG5PNTZrSUZJVTZIU1NWOXdkSzNkend0elpjcVdkUGo1UmdLQTMyM2RzZ2dXOUUyRDNlUkNDZklWa1hlWXVWZmNLSUlva2xvdTFzckVNMmRmbllPOVJ1TlNaQWVmSW9zNlJNZQ?oc=5","date":"2020-11-10","type":"pipeline","source":"Fierce Pharma","summary":"10 biotechs to know in China - Fierce Pharma","headline":"10 biotechs to know in China","sentiment":"neutral"}],"patents":[],"drugCount":27,"phaseCounts":{"phase_3":17,"phase_2":5,"phase_1":2,"marketed":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}